Brought to you by 
Inhale, Pharmacia develop PEGylated RA drug
Mar 2002
Executive Summary
Inhale Therapeutic Systems (drug delivery) has licensed its Shearwater subsidiary's PEGylation technology to Pharmacia for use with CDP870, an antibody fragment that just completed Phase II clinical trials to treat rheumatoid arthritis.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R+D and Marketing-Licensing
- Intra-Biotech Deal
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com